TRT Clinics Are Selling You Hormonal Chaos

The testosterone-to-IGF-1 pathway is not complicated once you see the whole chain, but most people selling you products along that chain are counting on you never seeing it in full.

Here is the map. Your liver produces something called IGF-1, which stands for insulin-like growth factor 1 and is the primary driver of tissue repair, muscle protein synthesis, and lean mass maintenance in adults. The liver does not produce IGF-1 on its own initiative. It produces IGF-1 in response to growth hormone signals coming down from the pituitary gland. And the pituitary does not release growth hormone arbitrarily either. It releases growth hormone in response to hormonal conditions in the body, and one of the most important conditions it is reading is estrogen.

That is the chain. Testosterone converts to estrogen, estrogen signals the pituitary, the pituitary releases growth hormone, growth hormone tells the liver to produce IGF-1, and IGF-1 does the actual work in your tissues. Every link in that chain depends on the one before it.

Now here is where TRT clinics are creating a problem while selling you the solution.

When a man starts testosterone replacement therapy, his testosterone levels rise, and because testosterone aromatizes into estradiol through a process called aromatization, his estrogen levels rise with it. For many clinics, this triggers an automatic prescription of something called an aromatase inhibitor, most commonly anastrozole, which is a drug that blocks the enzyme responsible for converting testosterone into estrogen.

The logic they sell you is that high estrogen causes water retention, mood issues, and cardiovascular risk, so suppressing it protects you. And there is a kernel of truth in the water retention piece. But the framing is incomplete in a way that costs you.

When anastrozole suppresses estrogen, it does not just suppress estrogen in your bloodstream. It suppresses estrogen's signaling effect on the pituitary. The pituitary reads lower estrogen and reduces growth hormone output. Lower growth hormone output means the liver receives a weaker signal, and IGF-1 production falls. Research has consistently shown that estrogen is a primary regulator of IGF-1 synthesis in the liver, with some studies finding that suppression of estradiol in men can reduce IGF-1 levels significantly, sometimes in the range of 20 to 40 percent depending on how aggressively estrogen is suppressed.

So you started testosterone therapy to feel better, build muscle, recover faster, and have more energy. Then you were put on anastrozole, which crashed your estrogen, which lowered your growth hormone signal, which reduced your IGF-1, which is the molecule doing most of the work you were hoping testosterone would do. You are now spending money on a drug that is actively undermining the goal you were paying for in the first place.

This is where the next product enters.

Because now your IGF-1 is low, the same clinic can measure it, show you the number, and sell you injectable IGF-1 or a peptide protocol designed to raise it. The peptides most commonly used for this are things like ipamorelin or CJC-1295, which stimulate growth hormone release, or in more aggressive protocols, actual recombinant IGF-1 itself. Each of these costs money. Each of them is treating a problem that the anastrozole created. And the anastrozole was prescribed in response to estrogen elevation that was a direct consequence of the testosterone you are already paying for.

You are being charged at every stage of a loop that the clinic built.

The medical evidence for IGF-1 supplementation outside of a very specific clinical diagnosis is almost nonexistent. The approved use case for growth hormone replacement therapy, and by extension IGF-1 intervention, is something called growth hormone deficiency, which is a condition where the pituitary gland produces insufficient growth hormone due to damage, a tumor, or a congenital issue. This is rare enough that it is considered a niche endocrine disorder. The clinical guidelines for its treatment require documented deficiency confirmed through stimulation testing, meaning you cannot diagnose it from a single blood draw showing a low IGF-1 number, because IGF-1 fluctuates based on exactly the hormonal conditions we just described.

When a TRT clinic prescribes IGF-1 to a man with a functional pituitary and functional growth hormone axis, they are not treating a medical condition. They are treating a suppression that their own anastrozole protocol created, and the treatment is a pharmaceutical product they are selling you.

The question of whether this is ignorance or intent is worth sitting with. Anastrozole prescribing practices in the TRT space have shifted significantly over the past decade, and the research showing estrogen's role in IGF-1 synthesis and bone density and cardiovascular protection in men has been available for years. The idea that estrogen in men is simply a problem to be suppressed has been walked back substantially in the endocrinology literature. Studies examining men with naturally occurring aromatase deficiency, who cannot convert testosterone to estrogen at all, show severely impaired bone mineral density, metabolic dysfunction, and markedly reduced IGF-1 despite having high testosterone levels. The testosterone was there. Without the estrogen, the downstream effects did not follow.

That evidence has been in the literature long enough that any clinic prescribing anastrozole to men with estrogen levels in the normal physiological range, and then selling them IGF-1 peptides to compensate, either has not read it or has read it and is ignoring it.

The practical implication is this: if you are on testosterone therapy and you are also taking an aromatase inhibitor and your recovery, body composition, or energy has not improved the way you expected, the anastrozole is a reasonable place to look. Estrogen management in TRT is sometimes genuinely necessary, but the threshold for intervention matters, and the target is not zero or even low. It is a physiological range. Suppressing estrogen below that range in the name of symptom management, and then adding a separate product to address the downstream consequence of that suppression, is not medicine. It is a revenue model.

The body already knows how to make IGF-1. It needs testosterone to aromatize, estrogen to signal the pituitary, growth hormone to reach the liver, and a liver that is not being asked to process unnecessary pharmaceutical load. Every product inserted into that chain that is not fixing a documented deficiency is either duplicating what the body would do on its own or compensating for interference you are also paying for.

You do not need more products. You need the system to run the way it was designed to run.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness